GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting
SAN FRANCISCO, CALIFORNIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that it has been selected for an oral presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting taking place from November 4-8, 2026 in Phoenix, AZ.
Covered in this story
Call it yourself
No calls on $SITC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Site Centers Corp →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.